Summary of patient baseline and disease characteristics for E1609 patients randomized to the ipilimumab arms
| Characteristic | No. of patients (n=1034) | % |
| 5-year OS rate, 95% CI | – | 71 (68 to 74) |
| 5-year RFS rate, 95% CI | – | 48 (44 to 51) |
| Age, years | – | |
| Median | 54 | |
| Range | 18–80 | |
| Sex | ||
| Male | 670 | 64.8 |
| Female | 364 | 35.2 |
| ECOG PS | ||
| 0 | 865 | 83.6 |
| 1 | 167 | 16.2 |
| Missing | 2 | 0.2 |
| Breslow depth, mm | – | |
| Median | 2.5 | |
| Range | 0–6.7 | |
| Clark level | ||
| I | 10 | 1 |
| II | 30 | 2.9 |
| III | 119 | 11.5 |
| IV | 552 | 53.4 |
| V | 105 | 10.2 |
| Missing | 218 | 21.1 |
| AJCC stage group | ||
| IIIB | 548 | 53 |
| IIIC | 410 | 39.7 |
| M1a | 56 | 5.4 |
| M1b | 20 | 1.9 |
| Ulceration | ||
| No | 405 | 39.1 |
| Yes | 479 | 46.3 |
| Missing | 150 | 14.6 |
| Mitotic rate | ||
| 0 | 41 | 4.0 |
| 1 | 114 | 11.0 |
| 2 to 3 | 146 | 14.1 |
| 4+ | 491 | 47.5 |
| Missing | 242 | 23.4 |
| Treatment arm | ||
| Ipilimumab 3 mg/kg | 511 | 49.4 |
| Ipilimumab 10 mg/kg | 523 | 50.6 |
ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival; RFS, relapse-free survival.